News & Events

The value of our clients' news is directly related to the macro events and trends shaping the life sciences and healthcare industry. To appreciate one, you must fully understand the other.

Tiberend Strategic Advisors invites those interested in our firm and the companies we represent to access our News Feed and register for our Events Calendar.  Doing so, you will be assured to receive actionable information on the companies and trends that are defining the life sciences and healthcare space.

News Feed

     

Events Calendar

Nov 13 2018

OncoSec To Present Data in Late-Stage Triple Negative Breast Cancer (TNBC) at the 2018 San Antonio Breast Cancer Symposium®

Nov 8 2018

KemPharm, Inc. Reports Third Quarter 2018 Results

 

Nov 8 2018

Provention Bio Reports Third Quarter 2018 Financial Results and Provides Business Update

 

Nov 8 2018

OncoSec Appoints Robert Ward to its Board of Directors

Nov 8 2018

Marker Therapeutics to Present at Three Upcoming Healthcare Conferences

 

Nov 7 2018

OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial

 

Nov 6 2018

OncoSec Reports Preliminary Data from KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial of TAVO™ in Combination with KEYTRUDA® for Metastatic Melanoma at Society for Immunotherapy of Cancer's 33rd Annual Meeting

Nov 5 2018

Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease

 

Nov 5 2018

OncoSec to Host Conference Call to Review Preliminary KEYNOTE-695 Data

 

Nov 2 2018

OncoSec Announces Preliminary Data from KEYNOTE-695 Study Accepted for Late-Breaking Presentation at SITC Annual Meeting

Nov 1 2018

KemPharm to Report Third Quarter 2018 Results

 

Nov 1 2018

Provention Bio to Report Third Quarter 2018 Financial Results and Host Conference Call on Thursday, November 8, 2018

 

Oct 30 2018

KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ®

Oct 29 2018

OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer

 

Oct 24 2018

OncoSec Announces Publication of Data in Nature Gene Therapy Demonstrating the Ability of its Newly Optimized Intratumoral IL-12 Immunotherapy Platform to Increase Systemic Anti-tumor Responses in both Treated and Untreated Lesions

 

Oct 24 2018

KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting

Oct 23 2018

KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications

 

Oct 23 2018

Provention Bio Announces Completion of Enrollment of Phase 1b Clinical Trial of PRV-300 in Moderate-to-Severe Ulcerative Colitis

 

Oct 23 2018

Marker Therapeutics, Inc. Announces New Executive Appointments

Oct 23 2018

Ocugen to Highlight Phase 2 Clinical Data for OCU310 at AAO 2018

View more client news »